Intercept trial deaths unlikely associated with treatment, says Wedbush Wedush believes the two deaths that occurred during the FLINT Phase 2b trial disclosed late Friday by Intercept are unlikely related to the OCA treatment. The firm says any continued weakness in shares of Intercept would be a buying opportunity and keeps an Outperform rating on the name with a $493 price target.
News For ICPT From The Last 14 Days
Check below for free stories on ICPT the last two weeks.
Intercept started with Underperform, $172 target at FBR Capital FBR Capital initiated shares of Intercept with an Underperform rating and $172 price target. The stock closed yesterday at $296.36. FBR believes investors are too optimistic on the nonalcoholic steatohepatitis market and the company's path to commercialization for its obeticholic acid. The firm thinks Intercept may face payor pushback and restriction as its drug will be competing with hepatitis C treatments for dollars.